Drug Trial Radar · NCT02476123
Study of Combination Therapy With Mogamulizumab (KW-0761) and Nivolumab (ONO-4538/BMS-936558) in Subjects With Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Jun 11, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
118
Actual
Start
Jun 2015
Primary completion
Feb 7, 2018
Study completion Dec 21, 2018
Sponsor
- Lead sponsor
- Kyowa Kirin Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Ono Pharmaceutical Co., Ltd.
- First posted
- Jun 19, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to characterize the safety and tolerability and determine the maximum tolerated dose (MTD) or the recommended fixed dose of the combinations of Mogamulizumab and Nivolumab in subjects with locally advanced or metastatic solid tumors.
Conditions
- Solid Tumor
Interventions
Mogamulizumab: KW-0761, Nivolumab: (ONO-4538/BMS-936558)Biological
i.v. administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of subjects reporting adverse eventsTime frame: From the first dose of study medications until 90 days after the last dose of study medication
- Number of subjects reporting serious adverse eventsTime frame: From the first dose of study medications until 90 days after the last dose of study medication
- Percentage of subjects reporting serious adverse eventsTime frame: From the first dose of study medications until 90 days after the last dose of study medication
- Percentage of subjects reporting adverse eventsTime frame: From the first dose of study medications until 90 days after the last dose of study medication
- Number of subjects experiencing dose-limiting toxicityTime frame: For 28 days from the first dose of study medications
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Chiba, Japan
Site not named
Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.